Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206317 | 1.00 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL22364678 | 0.89 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL2009986 | 0.87 | PTPN1 (0.42) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL2009984 | 0.87 | PTPN1 (0.42) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL20054308 | 0.87 | CHRM2 (0.38) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL15116703 | 0.87 | CHRM2 (0.38) | HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1 | |
| SCHEMBL16824577 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1GPR119LMNA | |
| SCHEMBL16824578 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2NPC1GPR119LMNA | |
| SCHEMBL239567 | 0.86 | PTPN1 (0.36) | HSD17B10PTPN1CHRM2CHRM1CHRM3 | |
| SCHEMBL239566 | 0.86 | PTPN1 (0.36) | HSD17B10PTPN1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 442 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684615-A | Synthesis method of difluoro cyclobutane proline and derivative thereof | 吉尔多肽生物制药(大连市)有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4640684-A1 | KRAS G12D INHIBITORS AND USES THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| CN-119894891-A | KRAS G12D inhibitor and application thereof | 上海和誉生物医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024235121-A1 | FUSED RING COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-118684615-A | Synthesis method of difluoro cyclobutane proline and derivative thereof | 吉尔多肽生物制药(大连市)有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
| CN-1419541-A | Pharmaceutically active pyrrolidine derivatives as BAX inhibitors | APPLIED RES SYSTEMS AKS HOLDIN (NL) | 2003-05-21 | — | — | CN | disclosed |
| EP-1303486-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| EP-1268419-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| EP-1268418-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | Applied Research Systems ARS Holding N.V. (AN) | 2003-01-02 | — | — | EP | disclosed |
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
| WO-2002008185-A1 | PYRROLIDINE DERIVATIVES AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001074769-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001072705-A1 | PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-10-04 | — | — | WO | disclosed |
| WO-1995004718-A1 | 4-METHYLENEPROLINE DERIVATIVES AS FUNGICIDES | ZENECA LIMITED (GB) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | HSD17B10 1040/4885SMN1; SMN2 498/4885PTPN1 4092/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | HSD17B10 1989/4885SMN1; SMN2 4700/4885PTPN1 1325/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | HSD17B10 2484/4885SMN1; SMN2 266/4885PTPN1 3684/4885 |
| US-20020040146-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | HSD17B10 1522/4885SMN1; SMN2 3344/4885PTPN1 3435/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | HSD17B10 804/4885SMN1; SMN2 4493/4885PTPN1 920/4885 |
| US-12139497-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | HSD17B10 991/4885SMN1; SMN2 2468/4885PTPN1 3140/4885 |
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | HSD17B10 1885/4885SMN1; SMN2 459/4885PTPN1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.